NASDAQ NMS - GLOBAL MARKET · ALGS
-2.22% · -$0.1500 · Vol 109.5K
After hours · updated 19:08:43 ET
Aligos Therapeutics Inc

Aligos Therapeutics Inc

Biotechnology
$6.62
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is ALGS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for ALGS are being assembled.
About Aligos Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
82
Country
US

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.84
Day high
$6.85
Day low
$6.34
Previous close
$6.77
52W high
$6.85
-3.36% from high
52W low
$6.34
55% of range
Market cap
$41.9M
EPS
$-8.8900
Shares out
6.2M
Volume
109.5K
VWAP
$6.61
Price history computed in-house
SMA 50 $6.62 · above
SMA 200 $6.62 · above
52W position 55%
Veridion warehouse edge

Warehouse intelligence for ALGS.

Veridion Score
57
0: 681: 612: 393: 414: 795: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ALGS insider activity

Aligos Therapeutics Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for ALGS.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ALGS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALGS in this window.
Lobbying spend

ALGS lobbying filings, year to date.

Registered lobbying filings matched to Aligos Therapeutics Inc.

$160.0K
Refresh interval: 12hSource: LDA disclosure filings
Labor Issues/Antitrust/Workplace
Filing
$80.0K
ALIGOS THERAPEUTICS INC.

WILMER CUTLER PICKERING HALE AND DORR LLP

Apr 16, 2026
Filing
$80.0K
ALIGOS THERAPEUTICS INC.

WILMER CUTLER PICKERING HALE AND DORR LLP

Jan 18, 2026
Latest news · ALGS
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ALGS.
Options
Sovereign unlock shows live options positioning for ALGS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.